Tradewinds Capital Management’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.3K Hold
32
﹤0.01% 335
2026
Q1
$19K Hold
32
﹤0.01% 323
2025
Q4
$15.6K Hold
32
﹤0.01% 336
2025
Q3
$13.4K Hold
32
﹤0.01% 338
2025
Q2
$9.2K Hold
32
﹤0.01% 357
2025
Q1
$9.87K Hold
32
﹤0.01% 360
2024
Q4
$11.3K Hold
32
﹤0.01% 358
2024
Q3
$11.5K Hold
32
﹤0.01% 338
2024
Q2
$10.2K Hold
32
﹤0.01% 334
2024
Q1
$7.35K Hold
32
﹤0.01% 338
2023
Q4
$7.04K Hold
32
﹤0.01% 270
2023
Q3
$7.23K Hold
32
﹤0.01% 259
2023
Q2
$7.06K Hold
32
﹤0.01% 254
2023
Q1
$7.17K Hold
32
﹤0.01% 258
2022
Q4
$8.9K Hold
32
﹤0.01% 228
2022
Q3
$7K Hold
32
﹤0.01% 233
2022
Q2
$8K Hold
32
﹤0.01% 232
2022
Q1
$6K Hold
32
﹤0.01% 553
2021
Q4
$7K Hold
32
﹤0.01% 540
2021
Q3
$6K Hold
32
﹤0.01% 536
2021
Q2
$6K Hold
32
﹤0.01% 557
2021
Q1
$5K Hold
32
﹤0.01% 557
2020
Q4
$5K Hold
32
﹤0.01% 519
2020
Q3
$3K Hold
32
﹤0.01% 560
2020
Q2
$4K Hold
32
﹤0.01% 511
2020
Q1
$3K Buy
+32
New +$3.04K ﹤0.01% 519

Other funds holding UTHR

Tradewinds Capital Management's UTHR Position: Q2 2026 in Review

Tradewinds Capital Management held its United Therapeutics (UTHR) position steady in Q2 2026 at 32 shares worth $17.3K. The position accounts for ﹤0.01% of the portfolio, ranked #335.

Tradewinds Capital Management first reported a position in UTHR in Q1 2020 and has held it in 26 quarters since. The position peaked at $19K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Tradewinds Capital Management held 32 shares of United Therapeutics worth $17.3K as of Q2 2026.
  • Tradewinds Capital Management left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up ﹤0.01% of Tradewinds Capital Management's portfolio in Q2 2026, its #335 holding.
  • Tradewinds Capital Management first reported a position in United Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Tradewinds Capital Management's United Therapeutics position peaked at $19K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Tradewinds Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.